65,437 trials
Atopic Dermatitis
Primary: Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 — 16.3; 69.6; 79.7…
Lung Cancer
Primary: Toxic Death Rate — NA Participants
Metastatic Melanoma
Primary: Percentage of Participants With Overall Response (OR) — 38 percentage of participants
Critically Ill · Acute Kidney Injury
Primary: Death Within 7 Days — 4; 9; 6 Participants — p=0.52
Chronic Plaque Psoriasis · Moderate to Severe Chronic Plaque Psoriasis · Psoriatic Arthritis
Primary: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 — 4.8; 85.0; 49.7 percentage of participants — p=<0.001
Epilepsy · Dravet Syndrome · Lennox-Gastaut Syndrome
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Occurring in ≥5% of Participants in Any Treatment Group — 306; 353; 135; 140 participants
Older Adults · Physical Function · Cognitive Function
Primary: Curcumin and Physical Function -Walking — 0.014; 0.103 meters/second
Acute Lymphoblastic Leukemia, in Relapse
Primary: Duration of Asparaginase Activity >100 U/L During Induction — 18.9; 8.5 days
Stage III Intrahepatic Cholangiocarcinoma AJCC v7 · Stage IIIA Gallbladder Cancer AJCC v7 · Stage IIIB Gallbladder Cancer AJCC v7
Primary: Median Progression Free Survival (PFS) — 11.4; 14.9 months — p=0.62
Nonalcoholic Steatohepatitis (NASH) · Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events — 50; 60; 50; 25 percentage of participants
Impulsive Behavior
Primary: Stop Signal Task (SST) — 255; 215; 297 milliseconds
Neovascular Age-related Macular Degeneration
Primary: Systemic Adverse Events — 6; 5; 5; 11 Participants
Schizophrenia · Schizoaffective Disorder
Primary: Treatment Satisfaction — 5.25; 5.32 score on a scale
Multiple Myeloma
Primary: Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage — 0; 0; 0; 0 Participants
Alzheimer Disease · Dementia
Primary: Change in Physical Activity — 227; 282; 380; 232 minutes per week